American Society of Hematology

Baxalta’s shows positive data for BAX 855 in hemophilia A

Friday, July 17, 2015

Baxalta, a global biopharmaceutical provider dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, has published complete data from the phase II/III pivotal study and phase I trial of BAX 855 in Blood, the journal of the American Society of Hematology. BAX 855 is Baxalta’s investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], a treatment for hemophilia A with more than 11 years of real-world patient experience.

[Read More]

Andrew S. Kraft named director of University of Arizona Cancer Center

Monday, June 9, 2014

Dr. Andrew S. Kraft, a prostate cancer physician-scientist and cancer center administrator, has been named the Sydney E. Salmon endowed chair and director of the University of Arizona Cancer Center and associate vice president for oncology programs for the UA Health Sciences Center. In addition, Kraft joins the University as a tenured professor of medicine in the department of Medicine’s Division of Hematology/Oncology and senior associate dean for translational research in the College of Medicine.

[Read More]